Analysis of pegylated interferon alpha-2a efficacy in the treatment of chronic hepatitis C

Abstract

Objective To investigate the clinical efficacy and safety of the pegylated interferon alpha-2a(PEG -IFN-a-2a)in treatment of chronic hepatitis C. Methods 170 cases of patients with chronic hepatitis C were included in the study,by using digital table method they were randomly divided into two groups, the observation group of 85 cases were treated with PEG-IFN-alpha-2a therapy, and 85 cases in the control group using ordinary interferon alpha-2b therapy. Curative effect and safety of two groups of patients were compared. Results The observation group treated for 12 weeks,24 weeks and 24 weeks of alanine aminotransferase(ALT)and improvement rate were respectively 70.59%,80%,92.94%, which were higher than that of the control group(52.94%,62.35%and 70.58%)(χ2=5.42,6.71,4.83,all P<0.05). The observation group for 12 weeks,24 weeks and 24 weeks of HCVRNA negative rate were 64.71%,75.29%and 91.76%, obviously were higher than the control group of 50.59%,61.18%and 70.59%(χ2=4.28,7.68,6.31, all P<0.05). Adverse reaction rates were not statistically significant. Conclusion The pegylated interferon alpha-2a(PEG-IFN-a-2a)in treatment of chronic hepatitis C has a significant curative effect of PEG-IFN-alpha-2a therapy in chronic hepatitis C, which is better than the ordinary interferon alpha-2b, and is worthy of extensive promotion and application. Key words: Pegylated interferon-2a; Hepatitis B,hepatitis C,chronic; Clinical curative effect; Safety